These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
526 related articles for article (PubMed ID: 26541778)
61. Urokinase-Type Plasminogen Activator Receptor as a Potential PET Biomarker in Glioblastoma. Persson M; Nedergaard MK; Brandt-Larsen M; Skovgaard D; Jørgensen JT; Michaelsen SR; Madsen J; Lassen U; Poulsen HS; Kjaer A J Nucl Med; 2016 Feb; 57(2):272-8. PubMed ID: 26429955 [TBL] [Abstract][Full Text] [Related]
62. Targeting CAIX with [ Yang X; Zhu H; Yang X; Li N; Huang H; Liu T; Guo X; Xu X; Xia L; Deng C; Tian X; Yang Z Mol Pharm; 2019 Apr; 16(4):1532-1540. PubMed ID: 30803240 [TBL] [Abstract][Full Text] [Related]
63. Preclinical evaluation of anti-VEGFR2 monoclonal antibody ramucirumab labelled with zirconium-89 for tumour imaging. Novy Z; Janousek J; Barta P; Petrik M; Hajduch M; Trejtnar F J Labelled Comp Radiopharm; 2021 Jun; 64(7):262-270. PubMed ID: 33818828 [TBL] [Abstract][Full Text] [Related]
64. In Vivo Imaging of the Programmed Death Ligand 1 by González Trotter DE; Meng X; McQuade P; Rubins D; Klimas M; Zeng Z; Connolly BM; Miller PJ; O'Malley SS; Lin SA; Getty KL; Fayadat-Dilman L; Liang L; Wahlberg E; Widmark O; Ekblad C; Frejd FY; Hostetler ED; Evelhoch JL J Nucl Med; 2017 Nov; 58(11):1852-1857. PubMed ID: 28588151 [TBL] [Abstract][Full Text] [Related]
65. Comparison of two site-specifically (18)F-labeled affibodies for PET imaging of EGFR positive tumors. Su X; Cheng K; Jeon J; Shen B; Venturin GT; Hu X; Rao J; Chin FT; Wu H; Cheng Z Mol Pharm; 2014 Nov; 11(11):3947-56. PubMed ID: 24972326 [TBL] [Abstract][Full Text] [Related]
66. Immuno-PET Imaging of EGFR with Sarrami N; Wuest M; Paiva IM; Leier S; Lavasanifar A; Wuest F Mol Pharm; 2024 Nov; 21(11):5797-5806. PubMed ID: 39402973 [No Abstract] [Full Text] [Related]
67. Molecular imaging of platelet-derived growth factor receptor-alpha (PDGFRα) in papillary thyroid cancer using immuno-PET. Wagner M; Wuest M; Hamann I; Lopez-Campistrous A; McMullen TPW; Wuest F Nucl Med Biol; 2018 Mar; 58():51-58. PubMed ID: 29367096 [TBL] [Abstract][Full Text] [Related]
68. Novel radiolabeled peptides for breast and prostate tumor PET imaging: (64)Cu/and (68)Ga/NOTA-PEG-[D-Tyr(6),βAla(11),Thi(13),Nle(14)]BBN(6-14). Fournier P; Dumulon-Perreault V; Ait-Mohand S; Tremblay S; Bénard F; Lecomte R; Guérin B Bioconjug Chem; 2012 Aug; 23(8):1687-93. PubMed ID: 22770480 [TBL] [Abstract][Full Text] [Related]
69. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. Ping Li W; Meyer LA; Capretto DA; Sherman CD; Anderson CJ Cancer Biother Radiopharm; 2008 Apr; 23(2):158-71. PubMed ID: 18454685 [TBL] [Abstract][Full Text] [Related]
70. Copper-64 Labeled Macrobicyclic Sarcophagine Coupled to a GRP Receptor Antagonist Shows Great Promise for PET Imaging of Prostate Cancer. Gourni E; Del Pozzo L; Kheirallah E; Smerling C; Waser B; Reubi JC; Paterson BM; Donnelly PS; Meyer PT; Maecke HR Mol Pharm; 2015 Aug; 12(8):2781-90. PubMed ID: 26132879 [TBL] [Abstract][Full Text] [Related]
75. [ Liu S; Zhong J; Zhang Z; Zhao R; Yan Q; Wang X Eur J Nucl Med Mol Imaging; 2024 Oct; 51(12):3651-3661. PubMed ID: 38910166 [TBL] [Abstract][Full Text] [Related]
76. A new (68)Ga-labeled BBN peptide with a hydrophilic linker for GRPR-targeted tumor imaging. Pan D; Xu YP; Yang RH; Wang L; Chen F; Luo S; Yang M; Yan Y Amino Acids; 2014 Jun; 46(6):1481-9. PubMed ID: 24633452 [TBL] [Abstract][Full Text] [Related]
77. Impact of dianionic and dicationic linkers on tumor uptake and biodistribution of [ Mansour N; Dumulon-Perreault V; Ait-Mohand S; Paquette M; Lecomte R; Guérin B J Labelled Comp Radiopharm; 2017 Apr; 60(4):200-212. PubMed ID: 28129446 [TBL] [Abstract][Full Text] [Related]
78. In vitro and in vivo characterization of 64Cu-labeled Abegrin, a humanized monoclonal antibody against integrin alpha v beta 3. Cai W; Wu Y; Chen K; Cao Q; Tice DA; Chen X Cancer Res; 2006 Oct; 66(19):9673-81. PubMed ID: 17018625 [TBL] [Abstract][Full Text] [Related]
79. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer. Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667 [TBL] [Abstract][Full Text] [Related]
80. 64Cu-labeled 2-(diphenylphosphoryl)ethyldiphenylphosphonium cations as highly selective tumor imaging agents: effects of linkers and chelates on radiotracer biodistribution characteristics. Yang CT; Kim YS; Wang J; Wang L; Shi J; Li ZB; Chen X; Fan M; Li JJ; Liu S Bioconjug Chem; 2008 Oct; 19(10):2008-22. PubMed ID: 18763821 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]